Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Envisia Therapeutics

Request full access

Biotechnology company focused on the research and development of novel ocular therapies

Durham, United StatesFounded 2013Biotech & Life Sciences

About Envisia Therapeutics

Envisia Therapeutics operated as a clinical-stage biotechnology company, focusing on the development of extended-release ophthalmic therapies. The company was established in 2013 as a spin-out from Liquidia Technologies, launching with a significant $25 million Series A financing round. This initial funding was provided by investors including Canaan, New Enterprise Associates, and Wakefield Group. The company's operations were based in Research Triangle Park, North Carolina.

The core of Envisia's strategy was its proprietary PRINT (Particle Replication In Non-Wetting Templates) technology. This platform was engineered to create precisely manufactured, fully biodegradable particles for sustained drug delivery directly to the eye, addressing major ocular diseases. The technology allowed for the creation of injectable implants and suspensions capable of releasing therapeutics over several months from a single administration, thereby aiming to solve the prevalent issue of poor patient compliance with daily eye drops.

Envisia’s product pipeline targeted the leading causes of preventable blindness. Its lead candidate, ENV515, was a biodegradable travoprost implant for glaucoma, designed to lower intraocular pressure for more than six months. The company initiated a Phase 2a clinical trial for ENV515 in early 2015. Another key product in development was ENV1105, a dexamethasone implant for treating diabetic macular edema. In October 2017, Aerie Pharmaceuticals acquired the rights to Envisia's PRINT technology for use in ophthalmology, along with other assets including the ENV1105 candidate, for an upfront payment of $25 million. This event marked a significant milestone, leading to Envisia's status as being out of business following the asset acquisition.

Source: Dealroom company data

At a glance

Status
Closed
Employees
1
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Polymers, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B
Investment activity
1 company, latest Sep 2014
Capital deployed
$10M
Preferred round
SERIES A

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Mar 2016 $17M $66M Undisclosed —
DEBT✓Debt Oct 2015 $4.6M — Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Envisia Therapeutics website traffic

Latest recorded traffic for Envisia Therapeutics is 850 monthly website visits. Envisia Therapeutics's team grew 0% over the past year.

Latest monthly visits850 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Envisia Therapeutics in the Durham ecosystem

Live from Dealroom

The Envisia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Durham HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Envisia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Envisia Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.